Navigation Links
Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results
Date:3/7/2011

Both fourth quarter and full year 2010 net sales of Luvox CR include $2.0 million of revenue recorded as a result of a change in the timing of when revenue is recognized; the company now records Luvox CR sales upon shipment to distributors net of estimated returns.  The profit associated with this change has been excluded from the company's fourth quarter and full year 2010 adjusted net income.

"In 2010, our first full year of profitability, our progress included strengthening our balance sheet, enhancing our commercial business management team, significantly increasing Xyrem sales, and broadening our patent protection for sodium oxybate," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.  "We look forward to improving our performance in 2011, as we continue to grow and protect our Xyrem business and advance our intranasal clonazepam product candidate for acute repetitive seizures in epilepsy patients."

Research and development expenses for the fourth quarter of 2010 were $4.1 million, compared to $6.3 million for the fourth quarter of 2009.  Research and development expenses in 2010 were $25.6 million, compared to $36.6 million for 2009.  

Selling, general and administrative expenses for the fourth quarter of 2010 were $17.1 million, compared to $15.7 million for the fourth quarter of 2009.  In 2010, selling, general and administrative expenses were $69.0 million, compared to $58.7 million for 2009.

Interest expense for the fourth quarter of 2010 was $1.1 million, compared to $5.8 million for the prior year period.  Interest expense in 2010 was $12.7 million, compared to $22.8 million in 2009.  As of December 31, 2010, cash and cash equivalents were $44.8 million, an increase from $22.9 million at September 30, 2010.

2011 Financial GuidanceJazz Pharmaceuticals is providing full year 2011 financial guidance as follows:-- Total product sales

$ 232 - 245 mil
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ariz. , July 10, 2014   Ventana ...  Group, today announced it has entered into an agreement ... which operates as EMD Serono in the ... , to collaborate with Merck KGaA,s biopharmaceutical division on ... for an undisclosed target using Ventana,s proprietary diagnostic assays. ...
(Date:1/15/2014)... Sono-Tek Corporation (OTC BB: SOTK) today announced sales of  ... to sales of $2,202,000 for the prior year period, an ... also shown growth over the preceding quarter,s sales, continuing a ... year. Markets that experienced sales increases over the prior year ...
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
(Date:7/12/2014)... Passenger Information System market is estimated to grow from ... at an expected CAGR of 26.5% for the period ... in North America is well developed and network infrastructure ... the region. The growing ridership figures in public transport ... driving the North American Passenger Information System market at ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The rise ... has urged for new advanced network architectures to suit ... the IT industry with increasing cloud storage technologies. The ... advent of more mobility devices. This has resulted in ... the main driving forces for the SDN market. , ...
(Date:7/12/2014)... Dennis Thompson HealthDay Reporter ... way to guarantee that a surgical technique used to grind ... increase the risk of spreading cancer to other parts of ... advisory panel to the Food and Drug Administration also said ... power morcellation -- should sign a written consent stating that ...
(Date:7/12/2014)... July 12, 2014 In ... report, ‘cognitive assessment and training’ is defined ... assess, train, or enhance cognitive functions. These ... as in dementia screening, clinical trials, driver’s ... learning, self assessment, brain training, and employers’ ...
(Date:7/12/2014)... The Security Analytics market is estimated to grow ... 2019, at an expected CAGR of 9.7% for the ... the increasing number of security breaches, continued line of ... in organizations are enormous. Vendors in the security analytics ... to develop better and more secure systems. , There ...
Breaking Medicine News(10 mins):Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 4Health News:North America Software Defined Network (SDN) Market Worth $1,443.8 Million by 2019 - New Report by MicroMarket Monitor 5Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 2Health News:FDA Advisers Weigh Risks of Procedure for Removal of Uterine Fibroids 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4
... , Post-hoc analysis of two large clinical trials showed ... HDL, triglycerides and LDL than the pre-determined therapy alone ... (NYSE: ABT ) TRILIPIX (R) (fenofibric acid) ... and combined lipid targets in patients with mixed dyslipidemia ...
... Appoints Longtime Cardinal Health Executive to Advance Strategic Growth ... 8 Sarnova, the nation,s leading specialty distributor of health ... markets, announced today that it has appointed Hank Struik ... Cardinal Health, Inc., Mr. Struik, 42, brings more than ...
... Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the ... offer to acquire outstanding common stock purchase warrants. The ... the transactions described below will not be registered under the ... offered or sold in the United States absent registration or ...
... director of the CyberKnife Center of Miami ( http://www.cyberknifemiami.com ... by the South Florida Business Journal. , , According to Dr. ... as successful Miami businessmen who are among the upper echelon of leaders ... include the following people: , , , ...
... focus on family-building benefits for its employees , , ... CVS ) is proud to announce it has been named ... the country for offering superior family-building benefits, such as health ... adoptions, and paid and unpaid leave for birth and adoptions. ...
... On June 7th, Little Hearts, Inc. held their 13th ... the support services they offer is their "Picture of Hope" ... in age from infant to 50 of all different types ... TGA, TOF and Tricuspid Atresia. "HOPE" is shared with others ...
Cached Medicine News:Health News:Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets 2Health News:Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets 3Health News:Abbott's TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets 4Health News:Sarnova Names Hank Struik Chief Executive Officer 2Health News:Sarnova Names Hank Struik Chief Executive Officer 3Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 2Health News:Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants 3Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 2Health News:CVS Caremark Ranks Among 50 Best Fertility- and Adoption-Friendly Workplaces in America 3Health News:Members of National CHD Organization Unite for Little Hearts' Celebration and Assemble for 'Picture of Hope' 2
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... The new Synchron LXi 725 ... technology with highly accurate immunoassay testing ... sample handling on a single platform. ... are automatically repeated for optimal quality ...
...
...
Medicine Products: